BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

728

Sector

Pharmaceuticals

Calendar

19/02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/26/12	76.06 $	+3.72%	91,61,858
11/26/11	73.33 $	+1.19%	22,11,209
10/26/10	72.47 $	+0.25%	18,84,429
09/26/09	72.29 $	+6.23%	31,14,347
06/26/06	68.05 $	+6.78%	47,42,019

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

76.06USD

Average target price

94.60USD

Spread / Average Target

+24.38%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 13/02/2026 am IST			5-day change	1st Jan Change
76.06 ^USD	+3.72%		+19.35%	-0.56%

28/01	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
27/01	Intellia gets FDA nod to resume one gene therapy trial after safety pause	RE

Capitalization	1.41TCr 1.19TCr 1.09TCr 1.04TCr 1.93TCr 1,28000Cr 1.99TCr 13TCr 5.02TCr 62TCr 5.3TCr 5.19TCr 2,15400Cr	P/E ratio 2025 *	-22.1x	P/E ratio 2026 *	-45.5x
Enterprise value	1.53TCr 1.29TCr 1.17TCr 1.12TCr 2.08TCr 1,38300Cr 2.15TCr 14TCr 5.42TCr 67TCr 5.73TCr 5.61TCr 2,32700Cr	EV / Sales 2025 *	30.8x	EV / Sales 2026 *	16.7x
Free-Float	78.66%	Yield 2025 *	-	Yield 2026 *	-

28/01	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
27/01	Intellia gets FDA nod to resume one gene therapy trial after safety pause	RE
22/01	BridgeBio Pharma Inc issues $632.5 million convertible senior notes due 2033	RE
16/01	BridgeBio Prices $550 Million Convertible Senior Notes Offering	MT
15/01	BridgeBio Pharma Plans Offering of Senior Notes due 2033	MT
15/01	BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes	RE
13/01	BridgeBio Pharma Insider Sold Shares Worth $6,043,168, According to a Recent SEC Filing	MT
12/01	BridgeBio Pharma, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
12/01	BridgeBio Pharma reports Attruby product revenue $146 mln in Q4	RE
09/01	BridgeBio Pharma, Inc. - Special Call
06/01	BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says	MT
06/01	Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target	MT
17/12	BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing	MT

28/01	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
06/01	BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says	MT
06/01	Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target	MT
11/12	Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target	MT
08/11	BridgeBio Pharma, Inc. Presents Data from the ATTRibute-CM Study	CI

BridgeBio Pharma, Inc. Share Price

Equities

BBIO

US10806X1028

Pharmaceuticals

Valuation: BridgeBio Pharma, Inc.

Chart: BridgeBio Pharma, Inc.

Latest news: BridgeBio Pharma, Inc.

Last Transcript: BridgeBio Pharma, Inc.

Analysts' recommendations: BridgeBio Pharma, Inc.

Press Releases: BridgeBio Pharma, Inc.

News in other languages: BridgeBio Pharma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BridgeBio Pharma, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12/02	BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia	GL
28/01	CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
16/01	BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027	GL
15/01	BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027	GL
12/01	BridgeBio Pharma : corporate presentation january 2026	PU

13/02	Fármaco oral de BridgeBio mejora el crecimiento en niños con enanismo en estudio de fase avanzada
15/01	USA-Les valeurs à suivre à Wall Street (actualisé)
30/25/30	Wall Street : Toujours debout, mais légèrement chancelant
28/25/28	MÄRKTE USA/Fest - Börsianer setzen auf Entspannung zwischen USA und China
27/25/27	MÄRKTE USA/Fest - Neue KI-Chips beflügeln Qualcomm

1 day	+3.72%
1 week	+19.35%
Current month	-1.57%
1 month	-1.02%
3 months	+14.86%
6 months	+54.94%
Current year	-0.56%

1 week	67.82	84.94
1 month	62.84	84.94
Current year	62.84	84.94
1 year	28.32	84.94
3 years	10.57	84.94
5 years	4.98	84.94
10 years	4.98	84.94

Manager	Title	Age	Since
Francis McCormick PRN	Corporate Officer/Principal	75	01/04/2019
Neil Kumar CEO	Chief Executive Officer	47	01/04/2015
Charles Homcy PRN	Corporate Officer/Principal	77	01/02/2019

Director	Title	Age	Since
Charles Homcy BRD	Director/Board Member	77	01/11/2018
Eric Aguiar BRD	Director/Board Member	64	01/03/2019
James Momtazee BRD	Director/Board Member	54	01/03/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BRIDGEBIO PHARMA, INC.	+3.72%	+19.35%	+138.06%	+566.61%	1.41TCr
REGENERON PHARMACEUTICALS, INC.	+0.60%	+2.22%	+18.04%	+3.44%	7.99TCr
UCB	+3.67%	+2.70%	+44.51%	+246.19%	5.95TCr
CSL LIMITED	+0.89%	-14.89%	-39.52%	-49.63%	5.61TCr
SAMSUNG BIOLOGICS CO.,LTD.	+0.41%	+71.90%	+71.90%	+71.90%	5.47TCr
BIOGEN INC.	+2.25%	+5.47%	+46.52%	-31.71%	2.81TCr
INNOVENT BIOLOGICS, INC.	+0.06%	+11.51%	+150.99%	+106.25%	1.99TCr
INCYTE CORPORATION	+1.93%	-1.96%	+45.91%	+27.11%	1.97TCr
MODERNA, INC.	-0.99%	-1.86%	+31.36%	-76.31%	1.58TCr
SWEDISH ORPHAN BIOVITRUM AB	+0.59%	+14.56%	+28.31%	+68.00%	1.59TCr
Average	+1.32%	+1.85%	+53.61%	+93.19%	3.64TCr
Weighted average by Cap.	+1.35%	+0.60%	+38.27%	+70.70%

	2025 *	2026 *
Net sales	50Cr 42Cr 38Cr 36Cr 68Cr 4.49TCr 70Cr 442.78Cr 176.07Cr 2.16TCr 185.88Cr 182.07Cr 7.56TCr	91Cr 77Cr 70Cr 67Cr 124.08Cr 8.25TCr 128.32Cr 813.12Cr 323.34Cr 3.97TCr 341.35Cr 334.35Cr 14TCr
Net income	-68Cr -57Cr -52Cr -50Cr -92Cr -6.12TCr -95Cr -603.02Cr -239.8Cr -2.95TCr -253.15Cr -247.96Cr -10TCr	-34Cr -29Cr -26Cr -25Cr -46Cr -3.09TCr -48Cr -304.7Cr -121.17Cr -1.49TCr -127.91Cr -125.29Cr -5.2TCr
Net Debt	113.59Cr 96Cr 87Cr 83Cr 154.85Cr 10TCr 160.14Cr 1.01TCr 403.54Cr 4.96TCr 426.01Cr 417.28Cr 17TCr	106.71Cr 90Cr 82Cr 78Cr 145.46Cr 9.67TCr 150.43Cr 953.26Cr 379.07Cr 4.66TCr 400.18Cr 391.97Cr 16TCr